Get the Stockscreener App
2.56
21.23%
-0.69
After Hours:
2.70
0.14
+5.47%
Ensysce Biosciences Inc stock is traded at $2.56, with a volume of 60,342.
It is down -21.23% in the last 24 hours and down -52.50% over the past month.
See More
Previous Close:
$3.25
Open:
$2.91
24h Volume:
60,342
Relative Volume:
1.48
Market Cap:
$4.38M
Revenue:
-
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.8505
EPS:
-3.01
Net Cash Flow:
$-9.78M
1W Performance:
-28.89%
1M Performance:
-52.50%
6M Performance:
-28.89%
1Y Performance:
-78.40%
1-Day Range:
$2.5394
$3.135
1-Week Range:
$2.5394
$3.69
52-Week Range:
$2.118
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.56 | 4.38M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
Ensysce Biosciences raises $1.1 million in stock sale By Investing.com - Investing.com South Africa
Ensysce Biosciences raises $1.1 million in stock sale - Investing.com India
Ensysce Raises Fresh Capital: Strategic $1.1M Investment Powers Next-Gen Pain Drug Pipeline - Stock Titan
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting - ACCESS Newswire
(ENSC) On The My Stocks Page - news.stocktradersdaily.com
Ensysce Biosciences Advances in Opioid Innovation - TipRanks
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Revolutionary Opioid Safety Technology Takes Center Stage at PAINWeek 2025 - StockTitan
How the (ENSC) price action is used to our Advantage - news.stocktradersdaily.com
Zacks Small Cap Issues Negative Forecast for ENSC Earnings - Defense World
Ensysce Biosciences (ENSC) Projected to Post Earnings on Friday - Defense World
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - EIN News
When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St
Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Ensysce Biosciences, Inc. SEC 10-K Report - TradingView
Ensysce Biosciences Narrows Losses to $8M, Secures FDA Breakthrough Status - StockTitan
(ENSC) Long Term Investment Analysis - Stock Traders Daily
Ensysce Biosciences to Present Pain Management Innovations at ROTH Conference - StockTitan
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids - Marketscreener.com
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton Unive - GuruFocus
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website - ACCESS Newswire
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results - ACCESS Newswire
Ensysce Biosciences Regains Compliance with Nasdaq - ACCESS Newswire
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering - ACCESS Newswire
How To Trade (ENSC) - Stock Traders Daily
Revolutionary Pain Management: This New Opioid Actually Prevents Overdose - StockTitan
When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)? - Yahoo Finance
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic - ACCESS Newswire
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium - ACCESS Newswire
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - ACCESS Newswire
Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit - ACCESS Newswire
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate - ACCESS Newswire
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection - ACCESS Newswire
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - NEWSnet
Ensysce reports overdose protection in drug trial - Investing.com
Ensysce's PF614-MPAR Shows Breakthrough Overdose Protection in Phase 1b Opioid Trial - StockTitan
Biotech Steals The Show Following $14 Million Grant Announcement - MSN
Ensysce's Breakthrough Pain Drug Gets FDA Special Status; Secures $23.7M Funding Boost - StockTitan
Ensysce Biosciences (NASDAQ:ENSC) Shares Down 5.6% – Should You Sell? - Defense World
Ensysce Biosciences Regains Full Compliance with Nasdaq - Financial Content
Ensysce Biosciences Secures Critical Supply Deal for Breakthrough Overdose Protection Drug Development - StockTitan
983,518 Shares in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Bought by Anson Funds Management LP - MarketBeat
ENSC Stock Touches 52-Week High at $7.24 Amid Market Volatility - Investing.com Nigeria
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 - Marketscreener.com
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):